KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study.

Cheng Zhou, Bin Yang, Huiming Zeng, Rushan Xia, Ningning Dang, Qinping Yang, Ji Li, Chunlei Zhang, Guoqiang Zhang, Aihua Wei, Wei Lai, Shuxia Yang, Qingchun Diao, Yangfeng Ding, Liming Wu, Lunfei Liu, Danyang Jia, Hanjie Zhu, Jianzhong Zhang

Chin Med J (Engl) 139(7) 1054-1061

PMID40090937
PMCIDPMC13043251
DOI10.1097/CM9.0000000000003495
发表日期2025-03-17
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: Topical finasteride is a novel treatment for men with androgenetic alopecia (AGA). This study aimed to evaluate the efficacy and safety of topical finasteride spray solution in Chinese men with AGA. METHODS: This randomized, double-blind, placebo-controlled, phase III trial enrolled 270 individuals with AGA from 16 sites across China between December 2021 and March 2023. The participants were randomized at a ratio of 2:1 to receive either topical finasteride or placebo treatment once daily for 24 weeks. The primary endpoint was the change from baseline in target area (0.903 cm 2 area) hair count at week 24. The secondary endpoints were change from baseline in target area hair count at week 12, target area terminal hair count at weeks 12 and 24, target area terminal hair width at week 24, and target area hair width at week 24; an improvement of vertex hair growth assessed by the investigator at week 24; and the patient-assessed scores on the Male Hair Growth Questionnaire at week 24. RESULTS: A total of 270 individuals were enrolled and randomized, and 251 completed the study (165 in topical finasteride group, 86 in placebo group). Compared with the placebo group, in the topical finasteride group, the change from baseline in target area hair count was significantly higher at week 24 ( P <0.05), although it was only numerically higher at week 12 ( P = 0.0688). Significant differences favoring topical finasteride over placebo were observed for change from baseline in target area terminal hair count at weeks 12 ( P <0.05) and 24 ( P <0.01). The improvement of vertex hair growth assessed by the investigator was significantly greater in the topical finasteride group vs. the placebo group at week 24 ( P <0.01). Topical finasteride was generally safe and well-tolerated. CONCLUSIONS: In Chinese men with AGA, topical finasteride spray solution increased hair growth and showed good safety and tolerability profile during a 24-week treatment period. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05135468.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 The disposition of the participants with androgenetic alopecia. COVID-19: Coronavirus disease 2019.
非 KM Figure
Figure 2Figure 2 Efficacy outcomes in participants with androgenetic alopecia treated with topical finasteride versus placebo at weeks 12 and 24. (A) Change from baseline in target area hair count at weeks 12 and 24 in topical finasteride and placebo groups. (B) Change from baseline in target area terminal hair count at weeks 12 and 24 in topical finasteride and placebo groups. (C) Change from baseline in target area hair width at week 24 in topical finasteride and placebo groups. (D) Change from baseline in target area terminal hair width at week 24 in topical finasteride and placebo groups. (E) Improvement of vertex hair growth assessed by the investigator at week 24 (score results +1, +2, +3 were considered indicative of efficacious treatment). * P <0.05, † P <0.01. CI: Confidence interval; LSM: Least square mean; SE: Standard error.
非 KM Figure
Figure 3Figure 3 Baseline and week 24 dermatoscopic images of a participant with androgenetic alopecia treated with topical finasteride (the patient A).
非 KM Figure
Figure 4Figure 4 Photographic evaluation of the patient B with androgenetic alopecia in topical finasteride groups before the treatment and after the treatment.
非 KM Figure